Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 19/20 | 0.83 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16325190 | 0.91 | FASN (1.00) | FASN | |
| SCHEMBL16365759 | 0.91 | FASN (1.00) | FASN | |
| SCHEMBL16323182 | 0.88 | FASN (0.77) | FASN | |
| SCHEMBL16365760 | 0.88 | FASN (0.77) | FASN | |
| SCHEMBL18924345 | 0.87 | FASN (0.76) | FASN | |
| SCHEMBL19371749 | 0.86 | FASN (0.63) | FASNGPR119 | |
| SCHEMBL16324318 | 0.86 | FASN (0.75) | FASN | |
| SCHEMBL22259508 | 0.85 | FASN (0.61) | FASNGPR119 | |
| SCHEMBL16324419 | 0.85 | FASN (0.77) | FASN | |
| SCHEMBL19391337 | 0.85 | FASN (0.74) | FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3010916-B1 | 1,3-DIAMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-09-27 | — | — | EP | claimed |
| US-9670142-B2 | 1,3-diaminocyclopentane carboxamide derivatives | MERCK PATENT GMBH (DE) | 2017-06-06 | — | — | US | claimed |
| EP-3010916-A1 | 1,3-DIAMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES | Merck Patent GmbH (DE) | 2016-04-27 | — | — | EP | claimed |
| WO-2014202168-A1 | 1,3-DIAMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-12-24 | — | — | WO | claimed |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-16 | — | — | US | disclosed |
| EP-3010916-B1 | 1,3-DIAMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-09-27 | — | — | EP | disclosed |
| EP-3010916-B1 | 1,3-DIAMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-09-27 | — | — | EP | disclosed |
| US-9670142-B2 | 1,3-diaminocyclopentane carboxamide derivatives | MERCK PATENT GMBH (DE) | 2017-06-06 | — | — | US | disclosed |
| US-9670142-B2 | 1,3-diaminocyclopentane carboxamide derivatives | MERCK PATENT GMBH (DE) | 2017-06-06 | — | — | US | disclosed |
| US-9670142-B2 | 1,3-diaminocyclopentane carboxamide derivatives | MERCK PATENT GMBH (DE) | 2017-06-06 | — | — | US | disclosed |
| US-20160130214-A1 | 1,3-DIAMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-05-12 | — | — | US | disclosed |
| US-20160130214-A1 | 1,3-DIAMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-05-12 | — | — | US | disclosed |
| US-20160130214-A1 | 1,3-DIAMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | FASN 2790/4885GPR119 4121/4885 |
| US-20160130214-A1 | 1,3-DIAMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES | FASN, FADS1, FADS2 | FASN 1/4885GPR119 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.